Eli Lilly's stock, valued at $777.78 billion, sees strong investment despite slight earnings miss.
Eli Lilly and Company's stock has seen significant investment from firms like AllianceBernstein and Wellington Management, holding billions of dollars in value. Despite a slight miss on earnings expectations, with EPS of $5.32 versus the expected $5.45, analysts predict a strong year ahead with a forecasted 23.48 EPS. The stock, valued at $777.78 billion, has a high P/E ratio of 70.05, indicating investor optimism despite a recent sell-off by its chief accounting officer.
2 weeks ago
29 Articles
Articles
Further Reading
This is your last free story for the month. Don’t miss out — Subscribe now for unlimited access!